The Royal Marsden Hospital in London will take delivery early next year of a machine that combines radiotherapy with real time imaging using a magnetic resonance imaging (MRI) scanner.
Tumours can move quite perceptibly on a daily or even hourly basis, making precise targeting of the x ray beam difficult. The MR Linac, which is being developed in a collaboration between its manufacturers and medical centres around the world, aims to get around this difficulty by combining imaging with treatment, so that the x ray beam can be tailored to the tumour to deliver the radiation dose where it is needed and not to surrounding healthy tissue.
At a briefing at the Science Media Centre in London on 28 July, Uwe Oelfke, head of the joint department of physics at the Royal Marsden and the Institute of Cancer Research, said that the new machine consists of an MRI scanner around which rotates a linear accelerator that generates the x rays by accelerating electrons to nearly the speed of light. "We believe it will be able to reduce the radiation dose to healthy tissues by a factor of three," he said. "MRI scanning produces much more detail than x ray scanning, is non-invasive, and delivers no radiation dose. We should be able to obtain information about biological processes, including the response to treatment."
The system is being developed by Elekta, based in Stockholm, Sweden, which provided the radiotherapy part; and Philips, which supplied the imaging component. Combining the two technologies is a major challenge because the radiation treatment is affected by the powerful magnetic fields used in MRI, and the beam must pass through a gap in the specially designed magnet.
Nobody yet knows whether the system will work as planned, as no clinical trials have taken place. The Royal Marsden will be one of seven centres in the research phase of the project. For commercial reasons the machine's cost cannot be disclosed, but the Medical Research Council has provided a grant of £9.6m (€13.6m; $15m) for the initial programme. Kevin Harrington, a consultant at the Royal Marsden, said, "We need an evidence base to prove it will be valuable. So we plan a series of small clinical trials with a couple of dozen patients in each, which we'll compare with the outcome of existing standards of care."
The Institute of Cancer Research has planned nine major research themes to test the technology-in brain, lung, head and neck, oesophageal, pancreatic, rectal, breast, cervical, and prostate cancers. 
